Skip to main content

Table 1 Tumor surveillance program in VHL gene mutation-carriers

From: Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease

Age (y)

Physical exam

Fundoscopic examination

Urinary catecholamines

Brain/spinal imaging

Abdominal imaging

0 - 2

12 mo

24 mo

------

------

-----

2-10

12 mo

12 mo

12 mo

12 mo

-----

11-19

12 mo

6 mo

12 mo

12 mo

12 mo (US)

>20

12 mo

6 mo

12 mo

12 mo

12 mo (MRI)

  1. Mo: months; US: Ultrasonographic screening; MRI: Magnetic resonance imaging
  2. Adapted from: VHL family alliance http://www.vhl.org/handbook/vhlhb4.php#Suggested,
  3. Choyke et al, 1995 and Lonser et al, 2003.